Loading...
•
Jun 30, 2021
Cullinan Oncology Q2 2021 Earnings Report
Announced second quarter 2021 financial results and provided a corporate update.
Key Takeaways
Cullinan Oncology reported a strong cash position of $456.3 million as of June 30, 2021, and highlighted the IND clearance of two immuno-oncology pipeline programs, Cullinan MICA and Cullinan Florentine. Interim data from the Cullinan Pearl trial showed a disease control rate of 92% in the 100mg dose cohort.
Cullinan Pearl data showed increased disease control rate of 92% in the 100mg dose cohort.
IND clearance was received for two immuno-oncology pipeline programs: Cullinan MICA and Cullinan Florentine.
Clinical trial starts for Cullinan MICA and Cullinan Florentine are expected in 2H 2021.
Cash and investments totaled $456.3 million as of June 30, 2021.
Forward Guidance
Cullinan Oncology expects to provide updated preclinical data on Cullinan Amber and a clinical and regulatory update on Cullinan Pearl in the fourth quarter.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...